Cancer Stem Cells and Tumor Maintenance

Cancer stem cells (CSCs) are a subpopulation of tumor cells with dual properties: they self-renew indefinitely like normal stem cells while also driving tumor growth like cancer cells. Unlike rapidly dividing non-stem cancer cells that form the tumor's bulk, CSCs undergo asymmetric division, producing daughter cells that either retain stem potential or differentiate terminally. This heterogeneity makes tumors difficult to treat completely.

Cancer stem cells maintain tumors through multiple mechanisms. They secrete elevated vascular endothelial growth factors that generate new blood and lymphatic vessels, ensuring continuous nutrient supply. Additionally, CSCs can acquire increased invasiveness and migration ability, establishing secondary metastatic sites. Though non-stem cells form the tumor's major mass, CSCs drive long-term growth and progression.

Cancer stem cells employ multiple survival mechanisms to escape treatment. They increase drug efflux pump activation, enhance DNA repair activity, and express detoxification enzymes that reduce drug effectiveness. For example, in chronic myeloid leukemia, CSCs overexpress ABCB1 and ABCG2 membrane transporters that pump out imatinib mesylate, generating drug-resistant populations that survive therapy.

A single surviving cancer stem cell can reestablish the entire tumor population, resurrect the disease, and cause tumor relapse. Because CSCs retain self-renewal capacity and can differentiate into multiple cancer cell lineages, one cell is sufficient to regenerate a complete heterogeneous tumor with both stem and non-stem components.

Cancer stem cells arise from tissue-specific normal stem cells or progenitor cells through genetic alterations that reprogram their cellular pathways. Normal stem cells typically remain quiescent until stimulatory signals trigger proliferation or differentiation. Mutations transform these cells into CSCs that divide abnormally while maintaining stem cell properties, contributing to tumor progression.

Tumors contain genetically distinct cancer cell subpopulations with different properties and drug sensitivities. While most cancer therapies effectively target rapidly dividing non-stem cells, cancer stem cells survive through resistance mechanisms. This heterogeneity means therapies cannot eliminate all cancer cells simultaneously, allowing CSCs to persist and eventually cause recurrence.

The tumor microenvironment provides supplementary survival signals that enhance cancer stem cell drug resistance. Beyond their intrinsic survival mechanisms like increased drug efflux and DNA repair, CSCs benefit from epigenetic modifications and supportive signals from surrounding tumor tissue. This microenvironmental support contributes significantly to therapeutic resistance and tumor maintenance.